Loading
A phase 1/2 trial of CP-383 in colorectal cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder & urothelial cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Tasca Therapeutics, now recruiting.
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07030257 by Tasca Therapeutics, with 150 participants planned, started 2025-08-27 and due to reach its primary completion in 2028-08-15. Interventions recorded: CP-383.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.